Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis

Archives of Disease in Childhood

Volumn 78, Issue 6, 1998, Pages 536-539

  Vic, P ^a   Ategbo, S ^a   Turck, D ^a   Husson, M O ^a   Launay, V ^a   Loeuille, G A ^b   Sardet, A ^a   Deschildre, A ^a   Druon, D ^b   Arrouet Lagande, C ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b City Hospital   (France)

Author keywords

Aminoglycosides; Antibiotics; Cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

CEFTAZIDIME; TOBRAMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG SPUTUM LEVEL; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG INFECTION; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 15144357477     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.78.6.536     Document Type: Article

References (20)

1. Szaff M, Hoiby N, Flensborg W. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983;72:651-7.
2. Neijens HJ. Strategies and perspectives in treatment of respiratory infections. Acta Paediatr Scand 1989;363(suppl): 66-73.
3. David TJ. Cystic fibrosis. Arch Dis Child 1990;65:152-7.
4. Lindsay CA, Bosso JA. Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic consideration. Clin Pharmacokinet 1993;24:496-506.
5. Strandvik B, Hjelte I, Malmborg AS, Widen B. Home intravenous treatment of patients with cystic fibrosis. Acta Paediatr 1992;81:340-4.
6. Van Aalderen WM, Mannes GP, Bosma ES, Roorda RJ, Heymans HS. Home care in cystic fibrosis patients. Eur Respir J 1995;8:172-5.
7. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991;35:399-405.
8. Kovarik JM, Hoepelman IM, Verhoef J. Once-daily aminoglycoside administration: new strategies for an old drug. Eur J Clin Microbiol Infect Dis 1989;8:761-9.
9. Nordstrom L, Lerner SA. Single daily dose therapy with aminoglycosides. J Hosp Infect 1991;18(suppl A):117-29.
10. Pechere J, Craig W, Meunier F. Once-daily dosing of aminoglycoside: one step forward. J Antimicrob Chemother 1991;27(suppl C):149-52.
11. Vic P, Ategbo S, Turck D, et al. Tolerance, pharmacokinetics and efficacy of once-daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. Eur J Pediatr 1996;155:948-53.
12. Nelson J. Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal. J Pediatr 1985;106:1030-3.
13. Smith AL, Ramsey B, Redding G, Haas J. Endobronchial infection in cystic fibrosis. Acta Paediatr Scand 1989; 363(suppl):31-6.
14. Smith AL. Antibiotic therapy in cystic fibrosis: evaluation of clinical trials. J Pediatr 1986;108:866-70.
15. Sempe M, Pedron G, Roy-Pernot MF. In: Auxologie. Méthodes et séquences. Paris: Théraplix éd, 1979.
16. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-9.
17. Van Der Auwera P. Pharmacokinetic evaluation of single daily dose amikacin. J Antimicrob Chemother 1991;27(suppl C):63-71.
18. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 1984;105:117-24.
19. Guglielmo BJ, Quan LA, Stulbarg MS. Pharmacokinetics of once-daily versus thrice-daily tobramycin in CF patients. J Antimicrob Chemother 1996;37:1040-2.
20. De Broe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991;27(suppl C):41-7.